Completed OBSERVATIONAL NCT04241562

Validation of a Novel Cortical Biomarker Signature for Pain (PREDICT)

Sponsor: Neuroscience Research Australia

Conditions TMD

Interventions Injection of Nerve Growth Factor

Updated 8 times since 2020 Last updated: Apr 3, 2023 Started: Nov 4, 2020 Primary completion: Oct 10, 2022 Completion: Oct 10, 2022

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This observational or N/A phase trial investigates TMD and is currently completed. Neuroscience Research Australia leads this study, which shows 8 recorded versions since 2020 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

8 versions recorded

Sep 2024 — Present [monthly]

Completed
Jul 2024 — Sep 2024 [monthly]

Completed
May 2023 — Jul 2024 [monthly]

Completed

Status: Recruiting → Completed
Sep 2022 — May 2023 [monthly]

Recruiting
Apr 2022 — Sep 2022 [monthly]

Recruiting

▶ Show 3 earlier versions

Jan 2021 — Apr 2022 [monthly]

Recruiting
Dec 2020 — Jan 2021 [monthly]

Recruiting
Feb 2020 — Dec 2020 [monthly]

Recruiting

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Neuroscience Research Australia
University of Maryland, Baltimore

Data source: University of Maryland, Baltimore

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Baltimore, United States
• Sydney, Australia